Action VTI VISIONEERING TECHNOLOGIES, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Visioneering Technologies, Inc.

Actions

VTI

AU000000VTI2

Marché Fermé - Australian S.E.
Autres places de cotation
 07:52:47 02/05/2024 		Varia. 5j. Varia. 1 janv.
0,096 AUD -4,00 % Graphique intraday de Visioneering Technologies, Inc. -28,89 % -61,60 %
24/04 Transcript : Visioneering Technologies, Inc., Q1 2024 Earnings Call, Apr 23, 2024
28/02 Visioneering Technologies, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Visioneering Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Visioneering Technologies Releases One-Year Data from Myopia Progression Control Study
Visioneering Technologies Issues Part of Shortfall from Rights Offering
VTI gibt positive vorläufige 1-Jahres-Daten aus der klinischen PROTECT-Studie auf der Jahrestagung der American Academy of Optometry bekannt
VTI Announces Positive Interim 1-Year Data from the PROTECT Clinical Trial at American Academy of Optometry Annual Meeting
Visioneering Technologies Raising Funds for Clinical Trial, Business Expansion
VTI Appoints Dr. Juan Carlos Aragón as CEO and Executive Director
Visioneering Technologies Appoints CEO
Visioneering Technologies, Inc. Announces the Appointment of Juan Carlos Aragón as Chief Executive Officer, Effective 1 October 2023
Visioneering Technologies, Inc. Announces the Appointment of Juan Carlos Aragón as Executive Director, Effective 1 October 2023
Visioneering Technologies, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023
Visioneering Technologies Says Exposure to Collapsed Silicon Valley Bank is Minimal
Visioneering Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Visioneering Technologies, Inc. Announces Board Changes
Visioneering Technologies Hits 100% Enrollment Milestone for NaturalVue Multifocal Contact Lens Trial
Visioneering Technologies, Inc. Enrolls 100% of Subjects in its International Randomized Controlled Clinical Trial Known as PROTECT
Visioneering Technologies, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022
Visioneering Technologies : Appendix 4C and Business Activity Report - Jun-22 Qtr
Visioneering Technologies Reaches 50% Enrolment Milestone in Nearsightedness Clinical Trial
Visioneering Technologies, Inc. Achieves 50% Enrollment Milestone in its PROTECT International Clinical Study for Myopia Progression Control
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action VTI
  4. Actualités Visioneering Technologies, Inc.
  5. Autres langues